The landscape of new drugs in lymphoma

Anas Younes, Stephen Maxted Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Dec 29 2016

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Younes, A., Ansell, S. M., Fowler, N., Wilson, W., de Vos, S., Seymour, J., Advani, R., Forero, A., Morschhauser, F., Kersten, M. J., Tobinai, K., Zinzani, P. L., Zucca, E., Abramson, J., & Vose, J. (Accepted/In press). The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2016.205